Human Albumin Takeda (Human Serum Albumin)

Human Albumin Takeda is indicated for conditions where plasma volume or albumin levels need rapid restoration.

• Treatment of hypovolemia associated with trauma, surgery, or severe dehydration.
• Management of shock, including septic or hemorrhagic shock, when fluid resuscitation is required.
• Support for patients with extensive burns to compensate for protein loss.
• Correction of hypoalbuminemia in liver disease, nephrotic syndrome, or chronic malnutrition.
• Adjunct therapy during plasma exchange or apheresis procedures.

• Human Albumin Takeda works by increasing the concentration of albumin in the intravascular compartment, which raises plasma oncotic pressure. The elevated oncotic pressure draws water from the interstitial and intracellular spaces back into the vascular lumen, expanding circulating blood volume. By restoring oncotic balance, the solution helps maintain hemodynamic stability and improves tissue perfusion without directly affecting cardiac contractility or vascular tone.

Adverse reactions to Human Albumin Takeda are generally related to the infusion process and the protein content.

Common

• Mild fever or chills occurring during or within a few minutes after the infusion.
• Transient headache or dizziness that resolves without specific treatment.
• Nausea or vomiting that may appear during the infusion and subside shortly after.
• Localized rash, urticaria, or erythema at the infusion site indicating mild hypersensitivity.

Serious

• Anaphylactic or severe allergic reactions, such as bronchospasm, angio‑edema, or sudden hypotension, requiring immediate medical intervention.
• Volume overload leading to pulmonary edema or congestive heart failure, particularly in patients with pre‑existing cardiac disease.
• Hemolysis, renal impairment, or acute kidney injury reported in rare cases following high‑dose administration.
• Potential transmission of infectious agents, such as viruses or prions, despite rigorous donor screening and manufacturing controls.

When prescribing Human Albumin Takeda, clinicians should evaluate patient history and monitor for potential complications.

• Assess cardiac and renal function before infusion, as volume expansion may exacerbate heart failure or renal impairment.
• Verify that the patient has no known hypersensitivity to human albumin or any component of the solution.
• Use caution in patients with severe dehydration, sepsis, or uncontrolled hypertension.
• Monitor vital signs, fluid balance, and serum albumin levels during and after administration.
• Adjust infusion rate in individuals at risk for pulmonary edema or circulatory overload.
• Avoid concurrent administration with other colloid solutions unless clinically justified.

Human Albumin Takeda may interact with other medications or fluids that affect intravascular volume or immune response.

Avoid

• Simultaneous infusion of other colloid solutions (e.g., gelatin or dextran) that could increase the risk of hyperviscosity.
• Administration with high‑dose diuretics without careful monitoring of fluid status.

Use with caution

• Concurrent use of vasopressors, as rapid volume expansion may alter hemodynamic response.
• Blood products or plasma derivatives, which may compound protein load and affect coagulation.
• Certain antibiotics (e.g., aminoglycosides) that have nephrotoxic potential, especially in volume‑overloaded patients.
• Anticoagulants such as heparin, as changes in plasma volume may affect anticoagulant dosing and monitoring.